Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of N-3C01 alone and with PD-(L)1 antibody in advanced solid tumors
CTR20262119Phase 2Active
- Sponsor
- Hefei Xinzhu Biotechnology
- Start
- Jun 2026
- Countries
- 1
01
Overview
A Phase 2 trial of N-3C01 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma, sponsored by Hefei Xinzhu Biotechnology. Started Jun 2026; status: active.
02
Drugs
N-3C01
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on CTR20262119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262119.